[A clinical study on imipenem/cilastatin sodium in the field of pediatrics].
A clinical study on imipenem/cilastatin sodium (MK-0787/MK-0791) was carried out and the following results were obtained. MK-0787/MK-0791 was used for treatment of a total of 33 patients and clinical effectiveness, bacteriological efficacy and adverse reactions were evaluated. The clinical effects were excellent in 1 case, good in 21 cases and fair in 2 cases in a total of 24 cases with respiratory tract infections, were excellent in 5 cases and good in 1 case in a total of 6 cases with urinary tract infections, and were good in 2 cases and fair in 1 case in a total of 3 cases with gastroenteritis. Causative organisms isolated from 11 patients were 1 strain of Gram-positive cocci and 10 strains of Gram-negative bacilli. Ten out of 11 strains were eradicated for an eradication rate of 91%. The clinical efficacy was confirmed in 11 cases for an efficacy rate of 100%. The bacteriological study has shown that MK-0787/MK-0791 has a strong antimicrobial activity. No side effects were observed. There was only one abnormal laboratory finding, i.e., a case of eosinophilia.
D001424:Bacterial Infections / Q000188:drug therapy*; D002675:Child, Preschool; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage*; D004338:Drug Combinations; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005759:Gastroenteritis / Q000188:drug therapy; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D015378:Imipenem; D007223:Infant; D008297:Male; D009343:Neisseria; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem